EGFR exon 20 insertion mutation in non-small cell lung cancer: classification and clinical treatment research
10.16438/j.0513-4870.2020-1852
- VernacularTitle:非小细胞肺癌的EGFR外显子20插入突变: 分类及临床治疗研究进展
- Author:
Run LI
1
;
Hong-jie GUO
2
;
Xi CHEN
2
;
Ling DING
2
Author Information
1. Zhejiang Chinese Medical University, Hangzhou 310053, China
2. Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
- Publication Type:Research Article
- Keywords:
epidermal growth factor receptor;
exon 20;
insertion mutation;
tyrosine kinase inhibitor;
clinical treatment
- From:
Acta Pharmaceutica Sinica
2021;56(5):1201-1210
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, targeted therapy has become the standard treatment for advanced non-small cell lung cancer (NSCLC), but this treatment method has very limited effect on patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation. This insertion mutation is the third most common mutation in EGFR. It shrinks the drug binding pocket and gives tumors inherent resistance to available EGFR tyrosine kinase inhibitors (TKIs), resulting in the limited efficiency of the first and second generation of EGFR tyrosine. So far, no targeted therapy has been approved for NSCLC patients with EGFR exon 20 insertion mutations, and there are still no drugs that have met clinical needs. In this case, new treatment strategies using new EGFR TKIs or bispecific antibodies may establish new treatment standards for these patients in the future. In this review, we will summarize all relevant exon 20 insertions reported so far on the structure of EGFR and its influence on EGFR inhibitor sensitivity, as well as the treatment strategies of exon 20 insertions in NSCLC patients, hoping to be a clinical treatment for reference.
